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The aim of this study was to investigate the antiobesity and antihyperlipidemic eﬀects of vinegar-baked Radix Bupleuri (VBRB)
on high-fat diet- (HFD-) induced obese rats. After being fed HFD for two weeks, rats were dosed orally with VBRB or fenoﬁbrate,
once daily for further twelve weeks. VBRB (1.0gkg−1 per day) produced eﬀects similar to fenoﬁbrate (100mgkg−1) in reducing
body weight (BW) gain, visceral fat-pad weights, plasma lipid levels, as well as hepatic TG and cholesterol content of HFD-
fed rats. VBRB also lowered hepatic lipid droplet accumulation and the size of epididymal adipocytes in HFD-fed rats. VBRB
and fenoﬁbrate reversed the HFD-induced downregulation of hepatic peroxisome proliferator-activated receptor (PPAR)α. HFD-
induced reductions in the hepatic levels of acyl-CoA oxidase (ACO) and cytochrome P450 isoform 4A1 (CYP4A1) proteins were
reversed by VBRB and fenoﬁbrate. The elevated expression of hepatic sterol regulatory element binding proteins (SREBPs) in
HFD-fed rats was lowered by VBRB and fenoﬁbrate. The results of this study show that VBRB suppresses BW gain and body fat
accumulation by increasing fatty acid oxidation, an eﬀect which is likely mediated via upregulation of PPARα and downregulation
of SREBP expression in the liver of HFD-fed rats.
1.Introduction
Obesity is a common chronic disorder of carbohydrate and
fat metabolism, characterized by an excessive fat deposition
in adipose tissue and other internal organs, such as liver,
heart, skeletal muscle, and pancreatic islets [1]. Obesity
remains a major global public health issue because of its
increasing prevalence, which cuts across issues of sex, age
group, ethnicity, or race [1]. Obesity alone can induce all the
symptoms of metabolic syndrome, which is associated with
many additional health problems, including increased risk
of insulin resistance, nonalcoholic fatty liver, atherosclerosis,
degenerative disorders such as dementia, some immune-
mediated disorders such as asthma, and certain cancers
[2, 3]. Pharmacological approaches to weight control have
becomeanoverriding priority[4].Currenttrendsforobesity
management involve multiple pharmacological strategies,
including blocking nutrient absorption, modulating fat me-
tabolism, regulating adipose signals, and modulating the
satiety center. However, these approaches have been asso-
ciated with several serious adverse eﬀects in the clinic, in-
cluding adverse gastrointestinal eﬀects and signiﬁcant unfa-
vorable cardiovascular eﬀects [4]. As a result, a much safer
therapeutic approach is necessary.
RadixBupleuri,withaChinesenameChaihu,isrecorded
as the roots of Bupleurum chinense and B. scorzonerifolium
(family Umbelliferae) in the Chinese Pharmacopoeia, which
has been widely practiced to treat inﬂuenza, fever, malaria,
hepatitis, jaundice, nephritis, dizziness, bitter taste in the2 Evidence-Based Complementary and Alternative Medicine
mouth, lung diseases, cancer, and menstrual disorders in
China, Japan, and other Asian countries [5]. In previous
chemical studies on Bupleurum plants, saponins, ﬂavonoids,
coumarins, fatty acids, steroids, polysaccharides, and poly-
acetylenes were identiﬁed [5]. Among them saponins were
known to be the major bioactive compounds, which were
commonly used as chemical standards for quality evaluation
of Radix Bupleuri in the current Chinese Pharmacopoeia
andrecentpublications[6].WhenRadixBupleuriwasmixed
thoroughly with vinegar and then baked to dry, it was
changedtovinegar-bakedRadixBupleuri(VBRB).Thephar-
macological eﬀect and components in the drug changed a
little bit due to the vinegar-baked procedure [7]. It was
demonstrated that VBRB has a much stronger eﬀect on
acesodyne and bile secretion than that of the Radix Bupleuri
[8].Therefore,VBRBwasextensivelyusedintraditionalChi-
nese medicines for liver diseases treatment [9]. At present,
although there are some reports on the pharmacological
eﬀect of VBRB, little is known about the eﬀect of VBRB on
lipid regulation besides its clinical usage.
Diet-inducedobesityinrodentshasbeenusedasamodel
to investigate the interactions between the environment and
genetics. Rats fed a high-fat diet (HFD) become obese and
show distinctive visceral adiposity, dyslipidemia, hyperinsu-
linemia, and hepatic steatosis, which are typical of human
obesity [10]. Therefore, this study investigated the eﬀects of
VBRB on body fat and lipid proﬁles in rats with diet-induced
obesity and sought possible mechanisms of action.
2.Materials
2.1. Plant Preparations. The crude Radix Bupleuri was
purchasedfromJinbaoanTradeCo.,Ltd.(ZhunanTownship,
Miaoli County 350, Taiwan) in December 2010. The identity
of the plants was conﬁrmed by Hong T.Y. (Department
of Biotechnology, College of Pharmacy and Health Care,
Tajen University) using macroscopic and microscopic exam-
inations as well as thin-layered chromatography and high-
performance liquid chromatography (HPLC) methods. Ran-
dom ampliﬁed polymorphic DNA analysis was also applied
to identify DNA polymorphisms in crude Radix Bupleuri. A
voucher specimen (Lot No. 20101205) has been deposited at
our laboratory. The crude Radix Bupleuri was chopped into
small pieces (10kg) and incubated with vinegar (2kg); until
vinegar was totally absorbed into Radix Bupleuri. Then, the
material was dried by stir-ﬁring to obtain VBRB.
2.2. Analytical Method. VBRB was ground to a powder
and sieved through a 40-mesh screen. The powder was
dried at 60◦C until constant weight and was well-blended
before use. An ASE 100 System (Dionex, Sunnyvale, CA,
USA) with 34mL stainless steel ASE vessels was used for
the pressurized liquid extraction. Extraction conditions
were optimized by single-factor experiments (sequentially
varying the experimental parameters, one at a time, while
all the other parameters remained ﬁxed). The extract was
evaporated to dryness using a rotary evaporator under 45◦C.
The residue was then dissolved in 5.0mL of methanol and
ﬁltered through a 0.45μm nylon ﬁlter membrane prior to
injection into the HPLC system.
An Agilent 1100 HPLC system was used, equipped with a
quaternary pump, an autosampler, a degasser, an automatic
thermostatic column compartment, and a DAD detector.
Chromatography was performed on a TSKgel ODS-100V
C18 column (3μm, 15064.6mmid, Tosoh, Tokyo, Japan) at
a column temperature of 30◦C and a ﬂow rate of 1mLmin−1
using CH3OH (solvent A) and water (solvent B) as a mobile
phase with linear gradients: 0–60min (30–40% A), 60–
80min (40–50% A), and 80–90min (50–100% A). DAD was
set to monitor at 210nm, and the online UV spectra were
recorded in the range 190–400nm.
For LC-ESI-MS/MS analysis, an Agilent 1100 HPLC
systemcoupledwithaLC/MSDTrapXCTmassspectrometer
(Agilent Technologies, MA, USA) was used. The acquisition
parameters were as follows: collision gas, ultrahighpurity
helium; nebulizer gas, high purity nitrogen; nebulizer gas
(N2), 35 psi; dry gas (N2), 12Lmin−1;d r yt e m p e r a t u r e ,
350◦C; HV voltage, 3500V; mass range recorded mass-
to-charge ratio (m/z) 200–1600, target mass m/z 800;
compound stability, 100%; trap drive level, 100%; collision
energy (Ampl), 0.3–2V. Data-dependent MS/MS scanning
was used in negative-ion mode so that the two most
abundant ions in each MS scan were selected in turn and
subjectedtoIT-MS(MS/MS,withMS/MSrangingfrom2–4)
analyses.
A 1000μgmL −1 standard stock solution of saikosaponin
a (SSa, Sigma-Aldrich, Inc., Saint Louis, MO, USA) or
saikosaponin d (SSd, Sigma-Aldrich, Inc.) was prepared and
diluted in 10μgmL −1 to provide the working solution. To
determine SSa and SSd simultaneously, SSa and SSd were
used to prepare a series of standards having concentrations
of 12.5, 25, 50, 100, 250, and 400ngmL−1 in pure 70%
methanol solution and also in the extract from VBRB to
allow calibration of the samples. A calibration curve was
obtained by plotting the ratio of the peak areas of the
analyte and the IS as a function of the analyte concentration.
Aw e i g h t e d( 1 / x2) linear regression line was ﬁtted over
the concentration range from 12.5 to 400ngmL−1.T h e
concentrations of SSa and SSc in VBRB samples were
calculated from the ratios; they are expressed in units of
micrograms per gram of preparation powder.
2.3. Extract of VBRB. The extract of VBRB was carried out
according to the method reported previously [9]. Brieﬂy,
200g of VBRB was socked in 2000mL of water for 0.5h, and
then heated to boil, kept boiling for 45min, thereafter, ﬁl-
trated the extract. Gruﬀs were extracted again with 1600mL
ofwaterforafurther0.5h,pooledtheﬁltrate,andcondensed
to 200mL and then stored the extract at −20◦C until use.
2.4. Cell Culture. 3T3-L1 preadipocytes, obtained from
Bioresource Collection and Research Center (BCRC 60159)
of the Food Industry Research and Development Institute
(Hsinchu, Taiwan), were cultured in Dulbecco’s Modiﬁed
Eagle’s Medium (DMEM) (GIBCO BRL Life Technologies,
Invitrogen Corporation, CA, USA) with 10% fetal bovine
serum (FBS) (GIBCO BRL) and antibiotics (100unitsmL−1Evidence-Based Complementary and Alternative Medicine 3
penicillin and 100μgmL −1 streptomycin). When cells
were conﬂuent, diﬀerentiation was induced by adding
0.5mmolL−1 isobutylmethylxanthine (Sigma-Aldrich Co.)
and 1μmolL−1 dexamethasone (Sigma-Aldrich Co.) to the
cultures. After 2 days, cells were allowed to diﬀerentiate
further by adding 10% FBS and 10μgmL −1 insulin (Sigma-
Aldrich Co.) and the medium was changed every 2 days.
At day 10, about 80% of cultures were induced to contain
triglyceride (TG). Treatments including serum starvation
(DMEM only), SSa, SSd, or fenoﬁbrate (Sigma-Aldrich Co.)
were given to diﬀerentiated cultures for 8 hours. All other
reagents were of analytical grade.
2.5. Measurement of the Triglyceride Content. Oil Red O
(Sigma-Aldrich Co.) at 0.2% in isopropanol (Sigma-Aldrich
Co.) was mixed with water (3:2, vv−1) and ﬁltered. Exper-
imental cultured cells were washed with PBS, ﬁxed by 4%
paraformaldehyde(Sigma-AldrichCo.)inPBSfor5minutes,
incubatedwithﬁlteredOilRedOfor30minutes,andwashed
twicewithPBS.ThestainedTGwasextractedbyisopropanol
and its quantity was measured at 490nm absorbance [11].
A total of 5 independent experiments, with triplicates each,
were performed.
2.6. Animal Models and Treatment Protocols. Male Wistar
rats, 8 weeks of age, were obtained from the National
Laboratory Animal Center (Taipei, Taiwan). They were
maintained in a temperature-controlled room (25 ± 1◦C)
on a 12h:12h light-dark cycle (lights on at 06:00h) in the
animal center (Tajen University, Ping Tung Shien, Taiwan).
Food and water were available ad libitum. Regular rat chow
diet (RCD, #D12450B, Research Diets, New Brunswick, NJ)
with 20kcal% protein, 70kcal% carbohydrate, and 10kcal%
fat from lard was used as the maintenance and control
diet. A puriﬁed ingredient HFD with 20kcal% protein,
35kcal% carbohydrate, and 45kcal% fat primarily from
lard (#D12451, Research Diets) was used to induce a rapid
increase in body weight (BW) and obesity [12]. The caloric
density of the control diet was 3.85kcalg−1; that of the HFD
was 4.73kcalg−1. All animal procedures were performed
according to the Guide for the Care and Use of Laboratory
Animals of the National Institutes of Health as well as the
guidelines of the Animal Welfare Act. These studies were
conductedwiththeapprovaloftheInstitutionalAnimalCare
and Use Committee (IACUC) at Tajen University (approval
number: IACUC 98-13; approval date: October 19, 2009).
After being fed a HFD for two weeks, rats were dosed by
oral gavage once per day for 12 weeks with VBRB doses of
0.3, 0.5, and 1.0gkg−1 i nav o l u m eo f1 . 5m Lk g −1 distilled
water. Another group of HFD-fed rats was treated orally
for 12 weeks with 100mgkg−1 per day fenoﬁbrate. In folk
medicine, the recommended daily oral dose of VBRB is 3–
10g per adult per day. The dose of VBRB was calculated by
multiplying the recommended dose of intake per kilogram
by the human metabolism coeﬃcient to get the dose of
intake per day of rats according to the equation: the intake
dose per kilogram of rat body weight = recommended
intake dose for humans ÷ body weight 60kg × 6.25 [13].
The approximate daily oral dose of VBRB for a rat is
ranged from 0.3–1.0gkg−1. The dose of fenoﬁbrate was
based on studies with long-term fenoﬁbrate treatment in
rats [14]. A vehicle-control group of HFD-fed and RCD-
fed rats was treated with 1.5mLkg−1 distilled water only
over the same treatment period. Each experimental group
contained 8 rats in the study. Twelve weeks after treatment
with VBRB or fenoﬁbrate, HFD-fed rats were weighed
and anesthetized with sodium pentobarbital (30mgkg−1)
administeredintraperitoneally(i.p.),andbloodsampleswere
collected from the lateral tail vein. Feed and water were
supplied ad libitum throughout the 12-week experimental
period. Samples were centrifuged at 2,000×gf o r1 0m i n u t e s
at 4◦C. The plasma was then removed and placed into
aliquots for the respective analytical determinations. After
blood was collected, the liver and visceral and subcutaneous
white adipose tissues (WAT) were removed, rinsed with
physiological saline, weighed, and immediately stored at
−70◦C.
2.7. Biochemical Parameter Analysis. Diagnostic kits for the
measurement of plasma glucose (Cat. No. 10009582), total
cholesterol (TC; Cat. No. 10007640), and triglycerides (TG;
Cat. No. 10010303) were purchased from Cayman Chemical
Company (Michigan, USA). The diagnostic kit to determine
plasma and hepatic levels of high density lipoprotein choles-
terol (HDL-C) was purchased from Bio-Quant Diagnostics
(Cat. No. BQ 019CR, CA, USA), and low density lipoprotein
cholesterol(LDL-C)levelswerecalculatedusingFriedewald’s
equation [15]. Plasma-free fatty acid (FFA) levels were
determined using an FFA-quantiﬁcation kit obtained from
Abcam plc (Cat. No. ab65341, MA, USA). All samples were
analyzed in triplicate. Atherogenic index (AI) and coronary
risk index (CRI) were calculated as LDL-C/HDL-C and
TC/HDL-C, respectively [16, 17].
2.8. Extraction of Hepatic Lipid. A section of each liver was
collected for lipid content analysis. The liver (1.25g) was
homogenized with chloroform/methanol (1:2, 3.75mL),
and then chloroform (1.25mL) and distilled water (1.25mL)
were added to the homogenate and mixed well. After
centrifugation (1,500×g for 10min), the lower clear organic
phase solution was transferred into a new glass tube and
then lyophilized. The lyophilized powders were dissolved in
chloroform/methanol (1:2) as the hepatic lipid extracts and
stored at −20◦C for fewer than three days [18].
2.9. Hepatic Pathological Evaluation. Small pieces of hepatic
tissues taken from experimental animals were ﬁxed in
10% neutral formalin, dehydrated with alcohol, embedded
in paraﬃn, and sectioned to a mean thickness of 4μm.
Hematoxylin- and- eosin- (H&E-) stained tissues were
examined histologically to evaluate the index of diabetic-
induced necrosis. Liver biopsy was scored according to
the following criteria: grade 0: no steatosis, normal liver;
grade 1: <25% of hepatocytes aﬀected; grade 2: 26–50%
of hepatocytes aﬀected; grade 3: 51–75% of hepatocytes
aﬀected; and grade 4: >76% of hepatocytes aﬀected [19].
A total of 5 independent experiments were carried out for
statistical analysis.4 Evidence-Based Complementary and Alternative Medicine
2.10. Adipocyte Pathological Evaluation. Histological pho-
tomicrographs of adipose tissue were analyzed with a light
microscope using the paraﬃn method. Fresh tissues were
ﬁxed immediately in Bouin’s solution for 6 to 12 hours, and
then ﬁxed tissues were washed under running water. After
being dehydrated through diﬀerent grades of alcohol, the
tissues were embedded in paraﬃnb l o c ka t6 0 ◦C. Sections
(8μm) were cut and mounted on glass slides coated with
an egg albumin, and the paraﬃn was removed using xylene
and alcohol. The tissues were stained with H&E. After being
dehydrated and cleared of alcohol and xylene, the glass
slides were mounted in Canada Balsam. Photomicrographs
were taken with a Zeiss Axiolab light microscope equipped
with a Nikon Microﬂex HFX microscope camera. The sizes
of epididymal adipocytes were calculated using Image-Pro
Plus 7.0 (Media Cybernetics, MD, USA). A total of 5
independent experiments were carried out for statistical
analysis.
2.11.PreparationofHepaticFractions. Hepaticfractionswere
prepared as described previously [20]. To prepare nuclear
fractions, hepatic tissue was homogenized with ice-cold
lysis buﬀer containing 5mmolL−1 Tris-HCl (pH 7.5),
2mmolL−1 MgCl2, 15mmolL−1 LC a C l 2,1 . 5 m o l L −1 su-
crose, 0.1molL−1 dithiothreitol (DTT), and protease in-
hibitor cocktail. After centrifugation (10,500×gf o r2 0m i -
nutes at 4◦C), the pellet was suspended in extrac-
tion buﬀer containing 20mmolL−1 2-[4-(2-hydroxyethyl)-
1-piperazinyl]ethanesulfonic acid (pH 7.9), 1.5mmolL−1
MgCl2,0 . 4 2 m o l L −1 NaCl, 0.2mmolL−1 L EDTA, 25%
(vv−1) glycerol, 0.1molL−1 DTT, and protease inhibitor
cocktail. The mixture was placed on ice for 30 minutes. The
nuclear fraction was prepared by centrifugation at 20,500×g
for 5 minutes at 4◦C. The postnuclear fraction was extracted
from the liver of each rat as described below. In brief, hepatic
tissue was homogenized with ice-cold lysis buﬀer (pH 7.4)
containing 137mmolL−1 NaCl, 20mmolL−1 Tris-HCl, 1%
Tween 20, 10% glycerol, 1mmolL−1 phenylmethylsulfonyl
ﬂuoride, and protease inhibitor cocktail solution in DMSO.
The homogenate was then centrifuged at 2,000×gf o r
10 minutes at 4◦C. The protein concentration of each
fraction was determined using a commercial kit (Bio-Rad
Laboratories, Hercules, CA, USA).
2.12. Western Blot Analyses. For the determination of per-
oxisome-proliferators-activated-receptor(PPAR),sterol-reg-
ulatory-element-binding protein (SREBP)-1 and SREBP-
2, 30mg protein of each nuclear fraction was resolved
using 8% sodium dodecylsulfate polyacrylamide gel elec-
trophoresis (SDS-PAGE). Separated proteins were trans-
ferred electrophoretically to a nitrocellulose membrane,
blocked with 5% (wv−1) skim milk solution for 1 hour,
and then incubated with primary antibodies to PPARα
(Santa Cruz Biotechnology, Inc., CA, USA; Cat. No. sc-
1985),SREBP-1(SantaCruzBiotechnology,Inc.;Cat.No.sc-
367), SREBP-2 (Santa Cruz Biotechnology, Inc.; Cat. No. sc-
5603), or β-actin (Santa Cruz Biotechnology, Inc.; Cat. No.
sc-130656) overnight at 4◦C. After the blots were washed,
they were incubated with goat anti-rabbit and/or goat anti-
mouse IgG HRP-conjugated secondary antibody for 1.5
hours at room temperature. The blots were stripped with
Restore Western Blot Stripping Buﬀer (CANDOR Bioscience
GmbH, Wangen, Germany) for 15 minutes and incubated
with the antibodies. In addition, 30mg protein from each
postnuclear fraction for acyl-CoA oxidase (ACO; Santa Cruz
Biotechnology, Inc.; Cat. No. sc-98499) and cytochrome
P450 isoform 4A1 (CYP4A1; Santa Cruz Biotechnology,
Inc.; Cat. No. sc-53248) was subjected to 10% SDS-
PAGE. Each antigen-antibody complex was visualized using
ECL Western Blotting Detection Reagents and detected by
chemiluminescence with LAS-1000 plus (Fujiﬁlm, Tokyo,
Japan). Band densities were determined using ATTO Den-
sitograph Software (ATTO Corporation, Tokyo, Japan) and
quantiﬁed as the ratio to β-actin. The mean value for
samples from the vehicle-treated RCD-fed group on each
immunoblot, expressed in densitometry units, was adjusted
to a value of 1.0. All experimental sample values were then
expressed relative to this adjusted mean value. A total of
5 independent experiments were carried out for statistical
analysis.
2.13. Statistical Analysis. Data are expressed as the mean
± standard deviation (SD) for each group of animals at
the number (n) indicated in tables. Statistical analysis was
performed with one-way analysis of variance (ANOVA). The
Dunnett range posthoc comparisons were used to determine
the source of signiﬁcant diﬀerences where appropriate. A P
value <.05 was considered statistically signiﬁcant.
3. Results
3.1. Quantitative Analysis. The regression equations of SSa
and SSd are y = 190.65x − 1219.72 (R2 = 0.9992) and
y = 42.87x−111.25 (R2 = 0.9983), respectively. The content
of SSa (724.63 ± 0.06μg/g) was higher than that of SSd (9.62
± 0.04μg/g) in VBRB. The chromatogram of the sample
solution has been shown in Figure 1.
3.2. Eﬀects on Lipogenic Diﬀerentiated 3T3-L1 Adipocyte. SSa
and SSd exhibited a signiﬁcant concentration-dependent
decrease in the intracellular accumulation of TG in 3T3-
L1 adipocytes; the most signiﬁcant eﬀect (over 30% TG
reduction) was observed in treatment at 1μmolL−1 (n = 5;
Figure 2). Fenoﬁbrate (1μmolL−1) caused a decrease in the
TG content of diﬀerentiated 3T3-L1 adipocytes by 41% (n =
5; Figure 2).
3.3. Eﬀects on Body Weight (BW) and Food Intake. As shown
in Table 1, the BWs of HFD-fed rats in the drug-treated
and vehicle-treated groups were monitored over the 12-week
treatment period. At the end of treatment, the BW of VBRB-
treated rats (n = 8) was signiﬁcantly lower than that of rats
in the vehicle-treated group (n = 8). VBRB signiﬁcantly
suppressed BW gain at both the moderate (0.5gkg−1 per
day; n = 8) and high doses (1.0gkg−1 per day; n = 8).
Similar results were seen in rats treated with fenoﬁbrate
(100mgkg−1 per day; n = 8). No signiﬁcant diﬀerences inEvidence-Based Complementary and Alternative Medicine 5
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Figure 1: Mass chromatograms of (a) SSa and (b) SSd in VBRB
extract.
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Figure 2: Eﬀect of SSa, SSd, or fenoﬁbrate on triglyceride (TG)
content in 3T3-L1 adipocytes. The vehicle (distilled water) used to
solve the tested medications was given at the same volume. Values
were expressed as mean with SD (n = 5 per group) in each column.
aP<. 05 and bP<. 01 compared to the values of vehicle-treated
group.
daily food intake were observed among the groups over the
experimental period, despite the slightly higher water intake
observed in the vehicle-treated HFD-fed group as compared
to the others (n = 8; Table 1).
3.4. Eﬀects on Weight of White Adipose Tissue (WAT). The
weights of WAT from HFD-fed rats in the drug-treated
and vehicle-treated groups were assessed after the treatment
period (Table 1). Epididymal WAT, perirenal WAT, mesen-
teric WAT, and inguinal WAT weights were lower in VBRB-
treatedrats(n = 8)thanintheirvehicle-treatedcounterparts
(n = 8). A signiﬁcant (P<. 05) reduction in WAT weight
was seen with both the moderate (0.5gkg−1 per day; n = 8)
and high doses (1.0gkg−1 per day; n = 8) of VBRB. The
weight of epididymal, perirenal, mesenteric, and inguinal fat
pads was reduced signiﬁcantly by 27.5%, 29.6%, 28.5%, and
32.4%, respectively, in VBRB- (1.0gkg−1 per day) treated,
and HFD-fed rats compared with vehicle-treated, HFD-fed
rats (Table 1). Similarly, after treatment with fenoﬁbrate,
epididymal,perirenal,mesenteric,andinguinalfatpadswere
30.4%, 35.4%, 34.5%, and 36.4% lower, respectively, than in
their vehicle-treated counterparts (n = 8, Table 1).
3.5. Eﬀect on Plasma Lipids. The HFD caused elevated
concentrations of plasma TC, TG, and LDL-C (Table 2). The
moderate (0.5gkg−1 per day) and high doses (1.0gkg−1 per
day) of VBRB signiﬁcantly reduced plasma total TC levels
(23.5% and 31.5% reduction, resp.) compared with vehicle-
treated, HFD-fed rats (n = 8; Table 2). All doses of VBRB
decreased plasma TG levels in HFD-fed rats; the high doses
of VBRB reduced plasma TG levels in HFD-fed rats to 64.4%
of their vehicle-treated counterparts (n = 8; Table 2). The
low (0.3gkg−1 per day), moderate, and high doses of VBRB
signiﬁcantly reduced plasma LDL-C levels (23.0%, 38.2%,
and 43.3% reductions, resp.; Table 2). Plasma TC, TG, and
LDL-C concentrations were reduced signiﬁcantly by 38.4%,
47.3%, and 59.7%, respectively, in fenoﬁbrate-treated, HFD-
fed rats compared with vehicle-treated, HFD-fed rats (n = 8;
Table 2).
The plasma concentration of HDL-C in HFD-fed rats
was reduced to 59.3% of the level in the RCD-fed group
(n = 8; Table 2). After 8 weeks of treatment with VBRB
(1.0gkg−1 per day; n = 8) or fenoﬁbrate (n = 8), the plasma
HDL-CconcentrationinHFD-fedratswaselevatedtonearly
that of the RCD-fed rats.
Plasma FFAs were signiﬁcantly higher in vehicle-treated
HFD-fed rats compared to RCD-fed rats (Table 2). The
plasma FFA level was reduced by 37.4% in HFD-fed
rats treated with 1.0g/kg/day VBRB, compared with their
vehicle-treated counterparts (n = 8; Table 2). Fenoﬁbrate
treatment reduced FFA levels in HFD-fed rats by 46.4%
relative to the level in vehicle-treated, HFD-fed rats (n = 8
in each group; Table 2).
Fenoﬁbrate treatment arrested the elevation of AI and
CRI in HFD-fed rats (n = 8; Table 2). VBRB treatment also
caused a signiﬁcant (P<. 05) and dose-related reduction
in the atherogenic and coronary artery risk indices in the
HFD-fedratswhencomparedtothevaluesrecordedfortheir
vehicle-treated counterparts (n = 8; Table 2).6 Evidence-Based Complementary and Alternative Medicine
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3.6. Eﬀect on Hepatic Lipids. The hepatic TC level was
signiﬁcantly higher in HFD-fed rats than in rats from the
RCD-fed group (n = 8; Table 2). The hepatic TC levels were
reduced by 33.4% in HFD-fed rats treated with 1.0gkg−1
per day VBRB (n = 8; Table 2). Similarly, VBRB treatment
(1.0gkg−1 per day) also produced a signiﬁcant reduction
in hepatic TG concentration, to 64.5% of that in vehicle-
treated, HFD-fed rats (n = 8; Table 2). Hepatic TC and TG
levels were signiﬁcantly reduced (by 44.2% and 43.7%, resp.)
in fenoﬁbrate-treated rats compared with vehicle-treated,
HFD-fed rats (n = 8; Table 2).
3.7. Morphological Changes in Hepatocytes. HFD-fed rats
showed signiﬁcantly greater hepatic lipid accumulation than
RCD-fed animals (Figure 3). The extent of hepatic lipid ac-
cumulation after 12 weeks in fenoﬁbrate-treated, HFD-
fed rats was similar to that in RCD-fed rats (Figure 3).
HFD-fed rats treated with 1.0gkg−1 per day VBRB showed
considerably lower hepatic lipid accumulation than their
vehicle-treated counterparts (Figure 3). The pathological
grading of hepatic steatosis has been indicated in Table 3
(n = 5).
3.8. Morphological Changes in Epididymal Adipocytes. The
histological appearance of epididymal adipocytes was irreg-
ular in HFD-fed rats compared with animals in the RCD-
fed group (n = 5; Table 2). This morphological change
was not evident in HFD-fed rats after fenoﬁbrate treat-
ment (Figure 4). The histological appearance of epididymal
adipocytes in HFD-fed rats treated with 1.0gkg−1 per day
VBRB was not as normal as in fenoﬁbrate-treated rats,
but was better than in vehicle-treated controls (Figure 4).
Epididymal adipocytes were also signiﬁcantly larger in HFD-
fed compared to RCD-fed rats (Figure 4). The average size
of epididymal adipocytes was reduced by approximately
36.4% and 4.3%, respectively, in HFD-fed rats treated with
1.0gkg−1 per day VBRB or fenoﬁbrate compared with their
vehicle-treated counterparts (n = 5; Table 3).
3.9. Protein Expressions of PPARα,A C O ,C Y P 4 A ,a n dS R E B P s
in Hepatic Tissues. Hepatic PPARα protein expression in
HFD-fed rats was lower than that in RCD-fed animals, but
was elevated signiﬁcantly by treatment with 1.0gkg−1 per
day VBRB (Figure 5). In addition, the hepatic expression
levels of ACO and CYP4A proteins in HFD-fed rats were
markedly lower than in RCD-fed rats, but were signiﬁcantly
elevated in VBRB- (1.0gkg−1 per day) treated HFD-fed rats
(Figure 5). Similar results were seen in rats treated with
fenoﬁbrate.
The expression levels of hepatic SREBP-1 and SREBP-
2 proteins in HFD-fed rats were signiﬁcantly higher in
RCD-fed rats (Figure 5). The proteins levels of hepatic
SREBP-1 and SREBP-2 were decreased by 49.3% and 53.7%
in HFD-fed rats treated with VBRB (1.0gkg−1 per day),
relativetothoseinvehicle-treated,HFD-fedrats,respectively
(Figure 5). Hepatic SREBP-1 and SREBP-2 protein expres-
sion levels in HFD-fed rats treated with fenoﬁbrate were
48.1% and 43.1%, respectively, lower than those in their
vehicle-treated counterparts (Figure 5).
4. Discussion
In the this study, BW loss in HFD-fed rats was accompanied
by a depletion of body fat stores, since treatment with VBRB
also signiﬁcantly reduced the weight of the visceral and
subcutaneous WAT compared with that of vehicle-treated
HFD-fed rats. Excessive growth of adipose tissue results in
obesity, which involves two growth mechanisms: hyperplasia
(cell number increase) and hypertrophy (cell size increase)
[21]. The histological appearance of white adipocytes in
HFD-fed animals supplemented with fenoﬁbrate or VBRB
(1.0gkg−1 per day) was more regular, and adipocytes were
similar in size to those in RCD-fed rats. This suggests that
VBRBsuppressestheHFD-inducedincreaseinadiposetissue
mass and BW gain and that it may inhibit lipid accumulation
in adipose tissue in particular.
Obesity, especially abdominal obesity, is associated with
dyslipidemia, characterized by elevated TG and reduced
HDL-C concentrations [22]. TG is involved in the ectopic
accumulation of lipid stores in the liver and is associated
with a number of diseases such as metabolic syndrome and
type 2 diabetes [23]. High TC levels increase the risk of
developing coronary heart disease, and high levels of LDL-
C are a risk factor for coronary heart disease, while high
HDL-C is helpful in transporting excess cholesterol to the
liver for excretion in the bile [24]. As a result, HDL-C levels
are inversely related to coronary heart disease risk [25].
Similar to fenoﬁbrate treatment, the oral administration
of VBRB signiﬁcantly lowered plasma TC, TG, and LDL-
C levels in rats with HFD-induced obesity. Thus, VBRB
may be of beneﬁt to patients with hypercholesterolemia and
hypertriglyceridemia.
The eﬀect of VBRB on the atherogenic and coronary
artery risk indices is also notable. The ratio of total choles-
terol to HDL-C (i.e., the atherogenic index) and the ratio
of LDL-C to HDL-C (i.e., the coronary artery index) are
strong and reliable indicators of whether or not cholesterol
is deposited into tissues or metabolized and excreted [26].
The results of this study show that treatment with VBRB or
fenoﬁbrate causes profound reductions in the atherogenic
and coronary indices in experimental hyperlipidemic rats.
This strongly suggests that VBRB has therapeutic potential
for the management of obesity and hyperlipidemia and for
the prevention of atherogenic cardiovascular diseases.
Due to the ability of VBRB to reduce serum levels of
T G sa n dt o t a lc h o l e s t e r o l ,a sw e l la sa d i p o s et i s s u em a s sa n d
BW gain functions similar to those of PPARα activation;
we hypothesized that the actions of VBRB are related to
the regulation of hepatic expression of PPARα-target genes
involved in lipid metabolism. In hepatocytes and other
tissues (e.g., heart), ligand- (natural long-chain fatty acids)
activated PPARα binds to peroxisome proliferator response
elements of DNA and increases the transcription of genes
encoding enzymes involved in fatty acid oxidation and
lipoprotein metabolism [27]. The outcome is an increase
in hepatic fatty acid oxidation and ketogenesis, decreased
lipid levels in tissues, and protection against lipotoxicity.
We found that VBRB-treated HFD-fed rats had signiﬁcantly
higher hepatic PPARα protein, and that the eﬀect of VBRBEvidence-Based Complementary and Alternative Medicine 9
Vehicle-RCD
(a)
Vehicle-HFD
(b)
Fenoﬁbrate-HFD
(c)
VBRB 0.3-HFD
(d)
VBRB 0.5-HFD
(e)
VBRB 1.0-HFD
(f)
Figure 3: Histopathological ﬁndings in livers of HFD-fed rats receiving 12-weeks treatment with VBRB or fenoﬁbrate. Rats not receiving
any treatment were given the same volume of vehicle (distilled water) used to solve the test medications. Photomicrographs were taken at a
magniﬁcation of ×400. Photomicrographs are of tissues isolated from vehicle-treated RCD-fed rats (vehicle-RCD), vehicle-treated HFD-fed
rats (vehicle-HFD), VBRB- (0.3gkg−1 per day) treated HFD-fed rats (VBRB 0.3-HFD), VBRB- (0.5gkg−1 per day) treated HFD-fed rats
(VBRB 0.5-HFD), VBRB- (1.0gkg−1 per day) treated HFD-fed rats (VBRB 1.0-HFD), or fenoﬁbrate (100mgkg−1 per day)-treated HFD-fed
rats (fenoﬁbrate-HFD). The pathological grading of hepatic steatosis has been indicated in Table 3.
Table 3: Results of histopathological ﬁndings in livers and epididymal adipocytes of HFD-fed rats receiving 12-weeks treatment with VBRB
or fenoﬁbrate.
Groups Hepatic steatosis (0–4) Average sizes of epididymal adipocytes (μm2)
RCD-fed
Vehicle 0b 3160.5 ± 230.3b
HFD-fed
Vehicle 3.28 ± 0.56 5502.3 ± 210.9
VBRB (gkg−1 per day)
0.3 2.64 ± 0.61 4480.2 ± 156.2a
0.5 2.58 ± 0.74 4072.8 ± 181.3a
1.0 2.23 ± 0.53 3501.2 ± 148.2b
Fenoﬁbrate (100mgkg−1 per day) 2.12 ± 0.39a 3226.5 ± 174.6b
The vehicle (distilled water) used to solve the tested medications was given at the same volume. Values (mean ± SD) were obtained from each group of 5
animals in each group during after 12 weeks of the experimental period. The size and number of epididymal adipocytes in a ﬁxed area (1,000,000μm2)w e r e
measured. aP<. 05 and bP<. 01 compared to the values of vehicle-treated HFD-fed rats in each group, respectively.
was equivalent to that of fenoﬁbrate. It appears that VBRB
regulates the lipid proﬁle in HFD-fed rats through an
increase in hepatic PPARα levels. The discovery of VBRB as a
PPARα activator may oﬀer the promise of a novel class of an
antidiabetic drug.
Although reductions in lipogenic activity and in dietary
lipidabsorptionhavebeensuggestedascausesofthereduced
liver lipid content, an increased capacity of peroxisomal
β-oxidation (ACO) and microsomal ω-oxidation (CYP4A)
of fatty acids could also be contributing factors [28].
Elevated hepatic levels of ACO and CYP4A proteins imply
an enhanced oxidation of fatty acids in the peroxisomes and
microsomes of VBRB-treated, HFD-fed rats. These results
support the contention that VBRB, by directly or indirectly10 Evidence-Based Complementary and Alternative Medicine
Vehicle-RCD
(a)
Vehicle-HFD
(b)
Fenoﬁbrate-HFD
(c)
VBRB 0.3-HFD
(d)
VBRB 0.5-HFD
(e)
VBRB 1.0-HFD
(f)
Figure 4: Histopathological ﬁndings in epididymal white adipose tissue of HFD-fed rats receiving 12-weeks treatment with VBRB or
fenoﬁbrate. Rats not receiving any treatment were given the same volume of vehicle (distilled water) used to solve the test medications.
Photomicrographs were taken at a magniﬁcation of ×400. Photomicrographs are of tissues isolated from vehicle-treated RCD-fed rats
(vehicle-RCD), vehicle-treated HFD-fed rats (vehicle-HFD), VBRB- (0.3gkg−1 per day) treated HFD-fed rats (VBRB 0.3-HFD), VBRB-
(0.5gkg−1 perday)treatedHFD-fedrats(VBRB0.5-HFD),VBRB-(1.0gkg−1 perday)treatedHFD-fedrats(VBRB1.0-HFD),orfenoﬁbrate
(100mgkg−1 per day)-treated HFD-fed rats (fenoﬁbrate-HFD). Quantiﬁcation of the data is shown in Table 3.
activating PPARα, can upregulate the expression of genes
downstream of PPARα, which may lead to an enhanced
hepatic fatty acid oxidation and reduced TG content.
Thesterol-regulatory-element-bindingproteins(SREBPs)
are a family of three basic helix-loop-helix leucine zipper
transcription factors (SREBP-1a, -1c, and -2) that have been
identiﬁed as transacting factors involved in the maintenance
of intracellular cholesterol homeostasis, the control of fatty
acid metabolism, and the diﬀerentiation of adipocytes [29].
The SREBP-2 isoform activates genes of the cholesterogenic
pathway, whereas the SREBP-1 isoforms are more active
in regulating the synthesis of fatty acids [30]. It has been
documented that SREBPs were the upregulated genes related
to fatty acid synthase and cholesterol levels [20]. In the cur-
rentstudy,theelevatedexpressionsofSREBP-1andSREBP-2
in HFD-fed rats were signiﬁcantly decreased by the VBRB
(1.0gkg−1 per day) treatment. These results suggest that
VBRB has an ameliorating eﬀect on dyslipidemia through
the impaired hepatic SREBPs as well.
Three major oleanane saponins named SSa, SSc, SSd,
and many minor saponins are isolated from the roots of
Radix Bupleuri [6]. The following activities are reported for
SSa and SSd: anticancer, anti-inﬂammation, corticosterone
secreting, plasma-cholesterol-lowering action, hemolytic ac-
tivity, eﬀects on membrane ﬂuidity, and a protective action
against hepatic damage [5]. However, no such biological
activities are observed for SSc. Adipocytes play an important
role in lipid homeostasis and energy balance by relating to
TG storage and free fatty acids release [31]. The antiobesity
eﬀect therefore could be represented by the suppression of
TGformationin3T3-L1adipocytes.AntiobesityeﬀectofSSa
or SSd in the 3T3-L1 cell model was measured in our study.
We found that treatment with both saikosaponins reduced
TG content up to 30% at the concentration of 1μmolL−1,
which was similar to the eﬀect produced by fenoﬁbrate at
sameconcentration,whilethecontentofSSawashigherthan
that of SSd in VBRB. SSd seems to play a major role in the
attenuation of visceral fat accumulation and improvement of
hyperlipidemia produced by VBRB, providing a rationale for
the use of this product in lipid disorders regulation in folk
medicine.
Although we suggest that supplemental treatment with
VBRB may prevent or improve obesity by modulating lipid
metabolism caused by an excessive HFD, the results come
from rat studies and thus cannot be generalized to human.
Thus, placebo-controlled human studies are required to ﬁnd
the usability of this plant in human cholesterol/lipid/obesity
indications due to diﬀerent fat/lipid metabolism in humans
and rats. Also, safety testing should be taken with the
chronic consumption of large doses of traditional remedies,Evidence-Based Complementary and Alternative Medicine 11
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Figure 5: Representative immunoblots of protein expression of
PPARα, ACO, CYP4A, and SREBPs in hepatic tissues. Photomi-
crographs are of hepatic tissues isolated from vehicle-treated RCD-
fed rats (line 1), vehicle-treated HFD-fed rats (line 2), VBRB-
(0.3gkg−1 perday)treatedHFD-fedrats(line3),VBRB-(0.5gkg−1
per day) treated HFD-fed rats (line 4), VBRB- (1.0gkg−1 per day)
treated HFD-fed rats (line 5), or fenoﬁbrate- (100mgkg−1 per day)
treated HFD-fed rats (line 6). Rats not receiving any treatment were
given the same volume of vehicle (distilled water) used to solve the
test medications.
especially in in pregnant women, children, old people, and
people with kidney diseases; the results from rat studies
cannot be generalized to human.
5. Conclusion
TheresultsofthisstudyshowthatVBRBsuppressesBWgain
andbodyfataccumulationbyincreasingfattyacidoxidation,
an eﬀect which is likely mediated via the upregulation of
PPARα and downregulation of SREBP expression in the liver
of HFD-fed rats. SSd from VBRB could account for the
observed bioactivity. This experiment in rats did not give any
rationale to use VBRB in humans in these conditions due to
diﬀerent lipoprotein/lipid metabolism in rats and humans;
instead it may give rationale for controlled human studies.
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